Chemotherapy in Pregnancy: Assessing the Safety of Adriamycin Administration in Pregnancy Complicated by Breast Cancer
- PMID: 38204522
- PMCID: PMC10774876
- DOI: 10.1016/j.jaccas.2023.102141
Chemotherapy in Pregnancy: Assessing the Safety of Adriamycin Administration in Pregnancy Complicated by Breast Cancer
Abstract
Pregnancy-associated breast cancer is challenging to treat. Treatment with chemotherapeutic agents such as anthracyclines poses a risk of cardiotoxicity, despite being considered safe after the second trimester of pregnancy. Management requires multidisciplinary comanagement with cardio-obstetrics, cardiology-oncology, maternal-fetal medicine, and oncology.
Keywords: cancer; cardiomyopathy; pregnancy.
© 2023 The Authors.
Conflict of interest statement
Dr Guha is supported by the American Heart Association–Strategically Focused Research Network Grant in Disparities in Cardio-Oncology (#847740 and #863620) and the Department of Defense Prostate Cancer Research Program Physician Research Award #HT9425-23-1-0158; and has consulted for Myovant, Pfizer, and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
